[Pneumococcal disease and its prevention. The heptavalent pneumococcal conjugate vaccine]

Area of Science:

• Pediatric Infectious Diseases
• Vaccinology
• Public Health

Context:

• Pneumococcal disease poses significant morbidity, hospitalization, and mortality risks, particularly in children under five and adults over 65.
• The heptavalent pneumococcal conjugate vaccine (PCV7) was introduced in Spain in 2001, offering protection against key serotypes.
• PCV7 demonstrates immunological memory induction, distinguishing it from non-conjugate vaccines.

Purpose:

• To evaluate the efficacy, immunogenicity, and safety of the heptavalent pneumococcal conjugate vaccine in the Spanish pediatric population.
• To assess the vaccine's impact on invasive pneumococcal disease, pneumonia, and acute otitis media.
• To inform decisions regarding the inclusion of PCV7 in the national immunization schedule.

Summary:

• The heptavalent pneumococcal conjugate vaccine is immunogenic, safe, and efficacious in children under two years old.
• PCV7 effectively prevents invasive pneumococcal disease caused by the seven targeted serotypes, and also reduces pneumonia and acute otitis media.
• The vaccine covers 80% of serotypes responsible for invasive pneumococcal disease and acute otitis media in children aged 2-59 months in Spain.

Impact:

• The vaccine is primarily recommended for children under two, with consideration for children aged 2-5, prioritizing at-risk groups.
• Further understanding of pneumococcal disease epidemiology and PCV7 effectiveness in Spain is crucial for immunization policy.
• Successful implementation could significantly reduce the burden of pneumococcal disease in vulnerable pediatric populations.